目的 探討貝伐單抗注射液聯(lián)合卡培他濱片對晚期轉(zhuǎn)移性直腸癌患者血清表皮生長因子受體（EGFR）及人表皮生長因子受體（HER）表達(dá)的影響。方法 回顧性分析2014年10月—2017年10月到內(nèi)蒙古醫(yī)科大學(xué)附屬醫(yī)院診治的晚期轉(zhuǎn)移性直腸癌的患者84例，隨機(jī)數(shù)字表法分為兩組。對照組（42例）患者口服卡培他濱片，2 000 mg/m²，分2次服用，連續(xù)給藥2周。觀察組（42例）患者在對照組治療的基礎(chǔ)上第1天靜脈滴注貝伐珠單抗注射液7.5 mg/kg。3周為1個周期，療程為8個周期。比較兩組患者的療效、無進(jìn)展生存率、血清表皮生長因子受體（EGFR）及人表皮生長因子受體（HER）水平和生活質(zhì)量評分。結(jié)果 治療后，觀察組患者化療有效率和控制率分別為28.57%和59.52%，明顯高于對照組患者的11.90%和38.10%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，觀察組患者6個月、1年和2年無進(jìn)展生存率分別為92.85%、80.95%和59.52%，明顯高于對照組患者的80.95%、57.14%和38.10%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組EGFR及HER水平均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組降低幅度明顯大于對照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組物質(zhì)生活、軀體功能、社會功能和心理功能評分均較治療前有所降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；但觀察組患者各項(xiàng)評分降低幅度明顯小于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間兩組患者骨髓抑制、胃腸道反應(yīng)、高血壓、蛋白尿及鼻出血等不良反應(yīng)發(fā)生率未表現(xiàn)出明顯差異。結(jié)論 貝伐單抗注射液聯(lián)合卡培他濱片能夠有效延緩?fù)砥谵D(zhuǎn)移性直腸癌患者病情進(jìn)展，提高患者生活質(zhì)量，且不增加不良反應(yīng)發(fā)生率，建議臨床推廣應(yīng)用。

Objective To explore the efficacy of Bevacizumab Injection combined with Capecitabine Tablets on expression of EGFR and HER in treatment of metastatic rectal cancer in advanced stage. Methods Patients (84 cases) diagnosed with metastatic rectal cancer in advanced stage in The Affilitated Hospital of Inner Mongolia Medical University from October 2014 to October 2017 were randomly divided into two groups. Patients (42 cases) in the control group were po administered with Capecitabine Tablets, 2 000 mg/m² for twice, and patients were treated for 2 weeks. Patients (42 cases) in the observation group were iv administered with Bevacizumab Injection 7.5 mg/kg at first day on the basis of control group. 3 weeks as one cycle, and the course of treatment was 8 cycles. Efficacy, progression-free survival rates, serum EGFR and HER levels, and quality of life score in two groups was compared. Results After treatment, the effective rate and control rate of chemotherapy in the observation group were 28.57% and 59.52%, respectively, which were significantly higher than 11.90% and 38.10% in the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, the progression-free survival rates at 6 months, 1 year and 2 years in the observation group were 92.85%, 80.95% and 59.52%, respectively, which were significantly higher than 80.95%, 57.14% and 38.10% of the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment,EGFR and HER levels in two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). And the decrease of the observation group was significantly greater than that of the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, the scores of physical life, physical function, social function and psychological function in two groups were reduced, and the difference was statistically significant in the same group (P<0.05). And the sores in the observation group were significantly lower than those in the control group, and the difference between the two groups was statistically significant (P<0.05). During the treatment, the adverse reaction incidences of bone marrow suppression, gastrointestinal reaction, hypertension, proteinuria, and nosebleed in two groups showed no significant difference. Conclusion Bevacizumab Injection combined with Capecitabine Tablets in treatment of metastatic rectal cancer in advanced stage can efficiently delay the disease progression,improve patients' quality of life, and do not increase the incidence of adverse reactions,which has clinical popularization and application.